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SUMMARY 
Background: The aim of this systematic review was to synthesize the results of original 
studies assessing antibiotic efficacy at different time points after initiating treatment in 
patients with a moderate probability of acute bacterial rhinosinusitis.  
Methodology: We searched the Cochrane library for systematic reviews on the efficacy of 
antibiotic treatment in patients with acute rhinosinusitis (ARS). Only randomized controlled 
trials (RCTs) that compared treatment of any antibiotic with placebo were included. 
Results: The synthesis of the results of six RCTs showed a benefit of antibiotic treatment 
compared to placebo for the rate of improvement after 3 [pooled odds ratio (OR) 2.78 (95% 
confidence interval (CI) 1.39 to 5.58)] and 7 [OR 2.29 (95% CI 1.19 to 4.41)] days after 
initiation in patients with symptoms and signs of ARS lasting for 7 or more days. After 10 
days [pooled OR 1.36 (95% CI 0.66 to 2.90)], improvement rates did not differ significantly 
between patients treated with or without antibiotics. 
Conclusions: Compared to placebo, antibiotic treatment relieves symptoms in a significantly 
higher proportion of patients within the first days of treatment. Reporting an overall average 
treatment efficacy may underestimate treatment benefits in patients with a self-limiting 
illness. 
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INTRODUCTION 
Antibiotics are effective in patients with acute rhinosinusitis (ARS) only in cases involving 
bacterial origin. Viruses cause most ARS, but discriminating between viral and bacterial 
rhinosinusitis is challenging and impossible in daily practice. In consequence, too many 
patients with ARS receive antibiotics [1-3]. Expert consensus guidelines recommend 
antibiotics only for patients with severe symptoms persisting for 10 days or more or for 
worsening of symptoms after initial improvement [4,5,1]. Authors who have synthesized the 
results from original studies on the efficacy of antibiotics did not address this specific patient 
population explicitly in their reviews, and their conclusions about the use of antibiotics in 
patients with ARS do not reflect agreement. One group of authors concluded that ARS 
resolves without antibiotic treatment [6], another group found that the overall efficacy of 
antibiotics is moderate [7], and a third group recommended prescribing the cheapest 
antibiotic [8]. 
The goal of systematic reviews is to support physicians and guideline developers in 
formulating their recommendations, but physicians sometimes have reservations about the 
results of these reviews, including a concern that some study results are synthesized that 
should not be [9]. Reasons for concern about synthesizing results from original studies 
include relevant differences among original studies in patient baseline characteristics or even 
unknown distributions of patient characteristics (e.g., duration of symptoms, fever present or 
not), differences in how (e.g., cure or improvement) and when (3, 10, or more days after 
treatment started) outcome was assessed, and inclusion of results from original studies with a 
moderate or even high risk of bias. A particular challenge is the synthesis of results from 
studies assessing treatment efficacy in patients with an illness such as ARS, for which even 
the presence or absence of the illness is difficult to establish. 
The aim of this review was to synthesize results from a set of original studies assessing 
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the efficacy of antibiotics compared to placebo in patients with a presumably moderate 
probability of ARS based on patient symptoms and signs. 
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MATERIALS AND METHODS 
Literature search 
We searched the Cochrane library for the terms “acute rhinosinusitis”, “acute sinusitis”, 
“antibiotic”, and “antimicrobial” in the title, abstract, or key words to identify systematic 
reviews on the efficacy of antibiotic treatment in patients with ARS. From the identified 
reviews, only randomized controlled trials (RCTs) that compared treatment of any antibiotic 
with placebo were eligible for further analysis. Non-randomized trials and observational 
studies were excluded. Our reporting is based on the recommendations of the PRISMA 
statement [10]. 
 
Eligibility criteria 
All RCTs included in the identified systematic reviews that met the following criterion were 
considered eligible: original studies that compared treatment of any antibiotic with placebo in 
patients with symptoms and signs of ARS lasting for 7 or more days with or without fever, 
i.e., a minimal duration of 7 or more days of symptoms and signs. The rationale to include 
only studies including patients with a duration of symptoms and signs (e.g., nasal discharge, 
purulent secretion, facial pain) lasting more than 7 days is based on the recommendation 
published in the “European Position Paper on Rhinosinusitis and Nasal Polyps” [1]. Those 
authors recommend antibiotic treatment only in patients with a duration of symptoms of more 
than 10 days. Because no original study was available that included only patients with this 
duration of symptoms, we modified the inclusion criteria for this review to 7 or more days. 
No limits for the study setting or language of the publication were applied. We excluded 
RCTs comparing treatment with any antibiotic versus any antibiotic. 
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Study selection, data extraction, and data synthesis 
The bibliographic details of all retrieved original studies were stored in an Endnote file. The 
full texts of the RCTs were reviewed by two reviewers independently (xx and xx). 
Researchers with specific language proficiencies were used for non–English language 
references. For each RCT included in this systematic review, both reviewers independently 
extracted data on study design, demographic characteristics, inclusion and exclusion criteria, 
duration of symptoms, treatment regimens including dosage and duration, use of concomitant 
drugs, clinical outcomes by group including number of patients and withdrawals, and time 
points of measurement. When the results of one original study were included in several 
publications, the most recent publication was chosen for this review, and missing information 
was added from previous publications. Disagreements were discussed and resolved by 
consensus or by third-party arbitration (xx). 
 
Outcomes 
The primary outcome of this systematic review focused on cure or improvement at different 
days of assessment. Cure was defined as complete resolution of signs and symptoms from 
rhinosinusitis, and improvement was defined as a reduction of signs and symptoms. 
Therefore, we categorized the following outcomes as cure: “restored” [11,12] and “entirely 
improved” [13]. “Much better” and “somewhat better” [11,12] were categorized as 
improvement. 
All patients who were categorized as cured are by definition improved; thus, we counted the 
number of improved and cured patients for the primary outcome of improvement. 
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Assessment of risk of bias 
Two reviewers (xx and xx) independently assessed the risk of bias of all included RCTs using 
the Cochrane Collaboration’s tool for risk-of-bias assessment [14]. Disagreements were 
resolved by consensus. 
 
Adverse events 
We collected data about adverse events following the addendum of the CONSORT statement 
for better reporting of harms in randomized trials [15]. 
 
Statistical analysis 
For the statistical analysis, we used R statistical software for Windows [16] and the package 
‘metaphor’ [17]. We classified the studies into two groups: The first group consisted of 
studies for which outcome was assessed at pre-specified time points (e.g., 3 days after 
randomization); in the second group, outcome was assessed at different days during a specific 
time frame (e.g., 7 to 12 days after randomization). We used a random effects model for 
pooling when I-squared was more than 50%. 
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RESULTS 
Study selection 
Fig. 1 summarizes the selection process for inclusion and exclusion. We identified seven 
systematic reviews assessing efficacy of antibiotics in patients with ARS [7,18-20,6,21,22]. 
In the seven systematic reviews, 21 RCTs were included comparing treatment of any 
antibiotic with placebo in patients with ARS. All were reviewed in full text, and six RCTs 
were eligible for our analysis, resulting in exclusion of 15 RCTs. Eleven of the excluded 
RCTs did not mention duration of symptoms in the set of inclusion criteria [23-33], two 
RCTs investigated rhinosinusitis only in children [34,35], the results of one RCT were not 
published [36], and one RCT did not report data on efficacy of antibiotic treatment compared 
to placebo at specified days after randomization [37]. 
 
Study characteristics 
Table 1 presents the study characteristics of all RCTs included in this systematic review and 
meta-analysis (detailed information about inclusion/exclusion criteria and outcome 
definitions are summarized in Supplementary Table 1). Two RCTs compared amoxicillin 
[38,13], one RCT moxifloxacin (fourth-generation fluoroquinolone) [39], and one RCT 
azithromycin (macrolide antibiotic) [40] with placebo. Two RCTs compared two antibiotics 
in separated groups (penicillin V and amoxicillin) versus placebo [11,12]. 
The most recent RCT was conducted in 2012 [38], and the years of publication were 
between 1996 and 2012. Five RCTs had a double-blind design [39,40,11-13], and one RCT 
was triple-blinded [38]. 
In total, 781 patients were included in the six RCTs, and 520 (67%) were females. 
Sample size ranged from 63 to 169 patients, and mean patient age was 37 years. No RCT 
reported the number of patients with fever at baseline. In four RCTs, the authors mentioned 
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the presence of fever in the set of inclusion criteria [39,11,12,38]; in one RCT, authors 
reported that the average body temperature was 36.7°C ± 0.5 [13]; and in the remaining 
study, the authors did not document the presence of fever [40]. Only Hadley et al. [39] 
mentioned fever as a compulsory inclusion criterion. Concomitant drugs were explicitly 
allowed in all RCTs except for Haye et al. [40], who did not report information about 
concomitant drug use. 
For the confirmation of bacterial origin of the ARS, only Hadley et al. [39] used sinus 
puncture and included only patients with positive cultures. Two RCTs took a sample either of 
nasal secretions [40] or from the nasopharynx [11], but verification of bacteria was not a 
mandatory inclusion criterion. Three RCTs did not report on sampling from the sinus or nasal 
secretions [38,12,13]. 
 
Risk of bias 
Table 2 shows the risk of bias of all included RCTs. Four RCTs were found to have a low 
risk of bias [40,11-13], and one RCT was found to have an uncertain risk of bias in one of the 
six domains [38]. The remaining RCT was found to have an uncertain risk in four of the six 
domains [39]. 
 
Efficacy of antibiotics 
Fig. 2 shows the odds ratios for the efficacy of antibiotics compared to placebo assessed at 
specific time points. Most RCTs showed a positive effect of antibiotic treatment over 
different observation periods (3–14 days). However, in many studies, the difference between 
antibiotics and placebo was not statistically significant. Lindbaek et al. (1996) [11] showed 
that treating patients with penicillin V or amoxicillin was significantly effective for the 
outcome ‘improvement’ at day 3 and for the outcome ‘cure’ at day 10. The pooled odds ratio 
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for improvement on day 3 was 2.78 [95% confidence interval (CI) 1.39 to 5.58]. The mean 
rate of improvement after 3 days was 66.4% (range 36.5% to 84.9%) in patients treated with 
antibiotics, and the mean rate in the placebo group was 44.4% (range 34.6% to 73.3%). In 
contrast, the pooled odds ratio for improvement on day 10 was 1.38 [95% CI 0.66 to 2.90]; 
for cure on day 10, it was 1.92 (95% CI 0.63 to 5.80). The mean rate of improvement on day 
10 was 87.6% (range 77.6% to 97.7%) in patients treated with antibiotics, and the mean rate 
in the placebo group was 84.8% (range 80.2% to 88.6%). 
Fig. 3 shows the odds ratios for the efficacy of antibiotics versus placebo assessed at 
different days during a specific time frame. Haye et al. [40] found a significant benefit for 
placebo treatment for the outcome ‘cure’ on days 10–12 but not on days 3–5 or 23–27. For 
the endpoint ‘improvement’, no significant differences were shown. The treatment with 
moxifloxacin in Hadley et al. [39] for the endpoint cure showed no significant effect. Because 
both studies assessed their outcomes at different time points (e.g., 3–5, 6–8, 10–12 days), we 
refrained from pooling the results. 
 
Relapse/Recurrence 
In Garbutt et al. [38], eight patients (9%) treated with amoxicillin had a relapse (see 
definition in Supplementary Table 1), and five patients (6%) treated with amoxicillin had 
recurrent symptoms (see definition in Supplementary Table 1). In the placebo group, five 
patients (6%) had a relapse, and two patients (2%) reported recurrent symptoms. In Haye et 
al. [40], four patients (5%) in the antibiotic group had a relapse between days 10–12 and 
seven patients (8%) between days 23–27. By contrast, only three patients (4%) treated with 
placebo had a relapse between days 10–12 and four patients (5%) between days 23–27. 
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Adverse events 
The recording and reporting of the adverse effects are summarized in Table 3. Data about 
adverse events were collected by personal (n=5) or telephone (n=1) [13] interviews. None of 
the six studies reported using a structured questionnaire or a patient diary to collect any 
adverse event. The evaluations (time frame of surveillance) were carried out between days 3–
27. All studies reported frequencies of adverse events, but only one study reported on severity 
of adverse events [11]. Between zero [13] and three patients [39] per study withdrew from the 
study because of an adverse event in the treatment group. The most frequent adverse events 
were headache, nausea/vomiting, and diarrhoea. Supplementary Table 2 shows the number of 
all adverse events for the treatment and placebo group per study. 
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DISCUSSION 
The synthesis of the results of the six RCTs shows a benefit of antibiotic treatment compared 
to placebo in patients with ARS symptoms and clinical signs for more than 7 days. Three and 
seven days after the initiation of an antimicrobial treatment, the rate of improvement in 
patients with antibiotics was significantly higher than in controls. After 10 days, there was no 
significant difference in the improvement rates between patients treated with or without 
antibiotics. ARS, with a few exemptions, is a self-limiting illness; therefore, the only small 
and non-significant difference after 10 days is not entirely unexpected. The number of 
adverse events reported in the original studies varied widely, from 5% to over 50%. The most 
frequently reported adverse effects were diarrhoea and nausea/vomiting, and only a small 
number of patients withdrew from the studies because of adverse events of antibiotic 
treatment. 
To our knowledge, this meta-analysis is the first to assess the outcome of improvement 
at specific time points (at days 3, 7, and 10). ARS is in general a self-limiting illness, and an 
effect of antibiotic treatment, if any, is expected after 2 to 3 days of treatment [38]. Six 
previous meta-analyses assessed clinical outcomes within different time frames (e.g., 3–5 
days, 7–11 days) [7,18-22], and in only one were results pooled for the endpoint ‘cure’ – 
indicating patients are free of any symptoms – at specific time points [6]. In four reviews, 
authors concluded that antibiotics exert a small benefit [19,20,18,7] whereas other authors 
concluded that antibiotics have no positive effect [6,21,22]. 
According to a guideline [5] and a position paper [1], antibiotic treatment is 
recommended for patients with a duration of symptoms, including fever, of 10 or more days 
or worsening of symptoms after initial improvement. The results of our review support the 
recommendations in the guidelines that antibiotics are effective for these patients. The 
proportion of patients with improvement of symptoms 3 and 7 days after starting treatment 
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was significantly higher in the group treated with antibiotics, and there seemed to be no 
relevant difference in the rate of improvement or cure rate after 10 days. For clinicians, the 
judgment to recommend antibiotics or not to patients with suspected ARS is challenging. 
Although the average efficacy of antibiotics measured 10 or more days after initiation of 
treatment seems to be insignificant, treatment with antibiotics is an option for patients who 
want to have a faster improvement of symptoms. 
Prevention of complications of bacterial rhinosinusitis, such as meningitis or orbital or 
brain abscess, is sometimes mentioned as a reason for antibiotic treatment [19]. These 
complications are rare but serious. In all six RCTs, patients with severe symptoms, e.g., high 
fever, were excluded. These patients might carry the highest risk for severe complications, 
and for clinicians, it may be important to know that these patients were not included in the 
original studies. 
In further clinical trials assessing the efficacy of antibiotic treatment in patients with 
ARS, methodological quality could be improved in two respects: precise reporting about the 
presence or absence of fever and recording and reporting of adverse effects. According to the 
guidelines, fever should be present in patients treated with antibiotics. In the published 
studies, we could not analyse patients with or without fever separately and compare the 
efficacy of antibiotic treatment between the two groups. Furthermore, an improvement in the 
recording and reporting of adverse effects would be very helpful for clinicians. The efficacy 
of antibiotic treatment in patients with ARS, even when present, is not very large. Therefore, 
knowledge about the frequency, severity, and duration of adverse effects is essential for 
advising patients about treatment. 
A strength of our study is that we pooled outcome results assessed at different, specific 
time points. Measurements within a time frame are more inaccurate because symptoms and 
signs can change quickly for illnesses such as ARS with a high rate of spontaneous 
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resolution. Furthermore, we included only RCTs that compared antibiotic treatment with 
placebo. We followed the general principle that head-to-head trials comparing the treatment 
effect of two or more antibiotics should be conducted when placebo-controlled trials have 
shown that treatment is better than placebo [41]. 
The main limitation of this study is the small number of RCTs available that compared 
antibiotic treatment with placebo in patients with ARS. Furthermore, inclusion criteria and 
definitions of outcomes as well as their assessment varied among the included RCTs. 
Our meta-analysis shows that antibiotic treatment compared to placebo relieves 
symptoms in a significantly higher proportion of ARS patients within the first days of 
treatment. However, the potential for adverse effects must be considered. In addition, in 
terms of the method of synthesizing results from original studies, reporting an overall average 
treatment efficacy in patients with an illness that has a high probability of spontaneous cure 
may underestimate treatment benefits. 
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Fig. 1 Study flow 
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Fig. 2 Efficacy of antibiotics assessed at specific time points 
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Fig. 3 Efficacy of antibiotics assessed at different days during a specific time frame 
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Table 1: Baseline characteristics of the six included RCTs 
 
Author, 
year 
Number 
of 
patients 
(women) 
Age 
mean: 
years 
(SD or 
range) 
Duration 
of 
symptoms: 
days (SD) 
Concomita
nt drugs 
allowed 
Intervention Control 
interventio
n 
Outcome 
classification 
Garbutt, 
2012 [38] 
166 (106) 31.5 
(18-69) 
7-28 (11.1) yes Amoxicillin 
500mg 
3x daily for 10 
days 
Placebo significant 
improvement, 
relapse, recurrence 
Hadley, 
2010 [39] 
118 (73) 38.5 
(13.4) 
7-27 (12.7) yes Moxifloxacin 
400mg 
1x daily for 5 days 
Placebo cure, improvement 
Haye, 1998 
[40] 
169 (125) 41.7 
(18-70) 
11-29 (n.r.) n.r. Azithromycin 
500mg 
1x daily for 3 days 
Placebo cure, improvement, 
failure, relapse 
Lindbaek, 
1996 [11] 
130 (85) 38.6 
(16-74) 
8-29 (n.r.) yes Group 1: 
Penicillin V 
1320mg 
Group 2: 
Amoxicillin 
500mg 
3x daily for 10 
days 
 
Placebo 
 
Placebo 
restored, much better, 
somewhat better, 
unimproved, worse 
Lindbaek, 
1998 [12] 
63 (38) 40.2 
(15.9) 
8-29 (n.r.) yes Group 1: 
Penicillin V 
1320mg 
Group 2: 
Amoxicillin 
500mg 
3x daily for 10 
days 
 
Placebo 
 
Placebo 
restored, much better, 
somewhat better, 
unimproved, worse 
Merenstein, 
2005 [13] 
135 (93) 33.8 
(9.8) 
≥7 (11.2) yes Amoxicillin 
500mg 
3x daily for 10 
days 
Placebo improved, not 
improved 
n.r. not reported 
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Table 2: Risk-of-bias assessment of all included RCTs 
 
Author, year Adequate 
sequence 
generation? 
Allocation 
concealment? 
Blinding? Incomplete 
outcome data 
addressed? 
Free of 
selective 
outcome 
reporting? 
Free of other 
bias? 
Garbutt, 2012 [38] + + + ? + + 
Hadley, 2010 [39] ? ? ? + + ? 
Haye, 1998 [40] + + + + + + 
Lindbaek, 1996 
[11] + + + + + + 
Lindbaek, 1998 
[12] + + + + + + 
Merenstein, 2005 
[13] + + + + + + 
+ low risk, ? uncertain risk, - high risk 
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Table 3: Recording and reporting of adverse events 
 
Author, 
year 
Drug 
therapy 
Number 
of patients 
with AEs 
n (%) 
Number of 
patients with 
treatment 
related AEs 
n (%) 
Number of 
patients with 
AEs in 
placebo 
group n (%) 
Withdrawa
l because of 
AEs (due 
to harm) n 
Seriousne
ss or 
Severity 
of AEs 
Evaluation 
of 
attribution: 
event related 
to antibiotic 
Data 
collection 
by 
personal 
interview 
Data 
collection 
by 
telephone 
interview 
Data 
collection by 
structured 
questionnair
e 
Data 
collection 
by 
patient 
diary 
Timefra
me of 
surveillan
ce (at 
day) 
Garbutt, 
2012 [38] 
Amoxicillin 14/85 
(16) 
not specified  11/81 (14) 1 n.r. n.r. yes no n.r. n.r. 10 
Hadley, 
2010 [39] 
Moxifloxacin 96/251 
(38.2) 
34/251 (13.5) 50/123 (40.7) 3 n.r. yes yes no n.r. n.r. 3-4, 6-8, 
14-18 
Haye, 1998 
[40] 
Azithromycin n.r. 24/87 (27.6) 15/82 (18.3) 0 n.r. yes yes no n.r. n.r. 3-5, 10-
12, 23-27 
Lindbaek, 
1996 [11] 
Penicillin V 24/41 
(58.5) 
not specified 16/44 (36.4) 2 reported n.r. yes no n.r. n.r. 3, 10 
Lindbaek, 
1996 [11] 
Amoxicillin 25/45 
(55.6) 
not specified 16/44 (36.4) 1 reported n.r. yes no n.r. n.r. 3, 10 
Lindbaek, 
1998 [12] 
Penicillin V 1 
(5)* 
not specified n.r. 1 n.r. n.r. yes no n.r. n.r. 10 
Lindbaek, 
1998 [12] 
Amoxicillin 2 
(9,1)* 
not specified n.r. 2 n.r. n.r. yes no n.r. n.r. 10 
Merenstein, 
2005 [13] 
Amoxicillin 13/57 
(22.8) 
not specified 7/59 (11.9) 0 n.r. n.r. no yes n.r. n.r. 3, 7, 14 
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Table 4: Reporting of adverse events 
 
Author, 
year 
Drug 
therapy 
Number of 
patients with 
AEs n (%) 
Number of 
patients with 
treatment 
related AEs n 
(%) 
Number of 
patients with 
AEs in 
placebo 
group n (%) 
Withdrawa
l because of 
AEs (due 
to harm) n 
Seriousne
ss or 
Severity 
of AEs 
Evaluation 
of 
attribution: 
event 
related to 
antibiotic 
Garbutt, 
2012 [38] 
Amoxicillin 14/85 
(16) 
not specified  11/81 (14) 1 n.r. n.r. 
Hadley, 
2010 [39] 
Moxifloxacin 96/251 
(38.2) 
34/251 (13.5) 50/123 (40.7) 3 n.r. yes 
Haye, 1998 
[40] 
Azithromycin n.r. 24/87 (27.6) 15/82 (18.3) 0 n.r. yes 
Lindbaek, 
1996 [11] 
Penicillin V 24/41 
(58.5) 
not specified 16/44 (36.4) 2 reported n.r. 
Lindbaek, 
1996 [11] 
Amoxicillin 25/45 
(55.6) 
not specified 16/44 (36.4) 1 reported n.r. 
Lindbaek, 
1998 [12] 
Penicillin V 1 
(5)* 
not specified n.r. 1 n.r. n.r. 
Lindbaek, 
1998 [12] 
Amoxicillin 2 
(9,1)* 
not specified n.r. 2 n.r. n.r. 
Merenstein, 
2005 [13] 
Amoxicillin 13/57 
(22.8) 
not specified 7/59 (11.9) 0 n.r. n.r. 
n.r. not reported, AE adverse event, * Only gastrointestinal AEs were reported 
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Supplementary Table 1: Inclusion and exclusion criteria, outcome definitions as reported in the original studies 
 
Author, 
year 
Study setting Inclusion criteria Exclusion criteria Outcome definitions 
Garbutt, 
2012 [38] 
10 offices of 
primary care 
physicians, between 
November 1, 2006 
and May 1, 2009, 
St. Louis, Missouri, 
USA 
Adult patients aged 18 to 70 years who met 
the Centers for Disease Control and 
Prevention’s expert panel’s diagnostic 
criteria for acute bacterial rhinosinusitis were 
assessed, if their symptoms were moderate, 
severe, or very severe. Diagnosis required 
history of maxillary pain or tenderness in the 
face or teeth, purulent nasal secretions, and 
rhinosinusitis symptoms for 7 days or more 
and 28 days or less that were not improving 
or worsening, or rhinosinusitis symptoms 
lasting for less than 7 days that had 
significantly worsened after initial 
improvement. 
Patients were excluded if they had an allergy 
to penicillin or amoxicillin, prior antibiotic 
treatment within 4 weeks, complications of 
sinusitis, a comorbidity that may impair their 
immune response, cystic fibrosis, required an 
antibiotic for a concurrent condition, were 
pregnant, or rated their symptoms as very 
mild or mild. 
significant improvement: 
self-rating: symptoms a lot better 
or absent (no symptoms) 
relapse: 
at day 10 significantly improved, 
but on day 28 symptoms 
unchanged or worse 
recurrence: 
at days 7 and 10 no symptoms, 
and at day 28 symptoms worse 
Hadley, 
2010 [39] 
37 centers (ear, 
nose, and throat 
practices; family 
practitioners; and 
general medical 
clinics), USA 
Patients were eligible for inclusion if they 
were ≥18 years of age and had a clinical 
diagnosis of ABRS with signs and symptoms 
present for ≥7 days but <28 days as defined 
by radiographic and clinical criteria. 
Radiographic criteria included the presence 
of air-fluid levels and/or opacification on a 
radiographic paranasal sinus film (Waters’ 
view). Eligible patients also had two major 
symptoms (purulent anterior or posterior 
nasal discharge and unilateral facial pain or 
malar tenderness), or at least one major and 
one minor symptom (frontal headache or 
fever [oral >38.0°C, tympanic >38.5°C, 
axillary ≥37.5°C]) as defined by the Sinus 
and Allergy Health Partnership. 
History of chronic sinusitis, defined as >4 
weeks of continuous symptoms; sinus 
surgery <6 months previously; symptoms 
that suggest the patient’s current illness is 
allergic rhinitis, known bacteremia, 
meningitis, or infection spreading beyond the 
sinuses; known immunodeficiency disease; 
receipt of systemic antibacterial therapy 
likely to be effective in the treatment of 
ABRS for >24 hours within 7 days of 
enrollment; requirement for concomitant 
systemic corticosteroids or systemic 
antibacterial therapy with agents other than 
those specified in the protocol; current 
receipt of topical nasal corticosteroids, unless 
the patient had been on a stable dose for >4 
weeks prior to enrollment; pregnancy or 
breast-feeding; receipt of an investigational 
cure: 
resolution or improvement in the 
signs and symptoms such that no 
further therapy (antimicrobial, 
corticosteroid or irrigation) was 
required 
improvement: 
improvement in the patient's signs 
and symptoms, and continuation 
of therapy 
- 30 - 
drug in the past 30 days; and a history of 
allergy to quinolone antimicrobials or related 
compounds 
Haye, 1998 
[40] 
General Practices, 
Norway 
Patients of either sex aged 18 to 70 years 
with a history of an upper respiratory tract 
infection and with clinical symptoms and 
signs indicative of but without radiological 
evidence of acute maxillary sinusitis were 
recruited and computer-randomized in blocks 
of six to either of the two treatment groups. 
The diagnosis was based on the physicians' 
clinical findings, which had to include one or 
both of the following symptoms: presence of 
nasal secretion (purulent at the time of 
examination) for >10 and <30 days, and 
maxillary sinus tenderness and/or pain of <30 
days' duration. To exclude the presence of 
empyema, plain radiographs using Waters' 
projection (occipitomental view) could not 
show complete opacity or an air-fluid level, 
and the mucosal thickness must be < 6 mm as 
measured at the upper lateral border of the 
maxillary sinus. In addition, radiographs 
using Caldwell projection (occipitofrontal) 
were performed to exclude frontal sinusitis 
and lateral projection to exclude sphenoidal 
sinusitis. 
Women who were pregnant or breast feeding 
or of child bearing potential but not using 
appropriate contraception, patients with a 
history of intolerance to macrolides, azalides, 
penicillin, or lactose, patients with more than 
two prior episodes of sinusitis during the last 
12 months, patients who had taken antibiotics 
within the preceding 2 weeks, those having 
extensive caries and/or periodontal disease, 
concurrent acute infections, or those using 
ergotamine. 
cure: 
disappearance of all pretreatment 
symptoms relevant to infection 
improvement: 
partial disappearance of 
pretreatment signs and symptoms 
failure: 
no change or a worsening of 
pretreatment symptoms 
relapse: 
initial improvement or 
disappearance of pretreatment 
symptoms followed by worsening 
Lindbaek, 
1996 [11] 
General practices, 
between January 
and May 1994 and 
between November 
1994 and May 
1995, Tønsberg 
region in southern 
Norway 
All patients were examined by one 
experienced general practitioner according to 
a standardised clinical procedure on the same 
day as the computed tomography was 
performed. The clinical signs and symptoms 
evaluated were scored according to being 
present or not or to severity. The symptoms 
and signs registered are all common in acute 
sinusitis. The presence of either hyposmia or 
anosmia, symptoms lasting longer than seven 
days before the first visit, unilateral facial 
Age 15 and under, pregnancy, ongoing 
antibiotic treatment, immunosuppressive 
treatment, previous operations in the nose or 
sinus region, misuse of alcohol or narcotics, 
rheumatic disease, and allergy to penicillin, 
symptoms persisted for more than 30 days 
(due to a possible chronic sinusitis), patients 
with high fever and strong pain (because of 
ethical consideration) 
 self-rating (restored, much better, 
somewhat better, unimproved, 
worse) without a more specific 
definition of these terms 
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pain, pain in upper teeth, pain worsening on 
bending forward, or two phases in the disease 
history each scored one point. Nasal 
obstruction, rhinorrhoea, sinus pain, and 
malaise estimated by the patient gave a 
maximum of one point each. Rectal 
temperature between 37.6 and 38.0°C scored 
0.5 and above 38.0°C one point. Purulent 
secretion in the nasal floor, which is a fairly 
consistent sign of purulent sinusitis, was 
given two points. The points were summated 
for each patient, resulting in a "clinical 
severity score" of a maximum of 13 points. A 
bacteriological sample from the nasopharynx 
was taken at the time of the clinical 
examinations. 
Lindbaek, 
1998 [12] 
General practices, 
between January 
and May 1994 and 
between November 
1994 and May 
1995, Tønsberg 
region in southern 
Norway 
Included were patients who were clinically 
diagnosed as having acute sinusitis, and had 
mucosal thickening without fluid levels or 
total opacification upon CT examination. All 
patients were examined by an experienced 
family physician according to a standardized 
clinical procedure, the same day as the CT 
was performed. The clinical signs and 
symptoms evaluated were scored according 
to being present or not, or to severity. The 
symptoms and signs registered are all 
common in acute sinusitis. The presence of 
either hyposmia or anosmia, duration of 
symptoms more than seven days prior to first 
visit, unilateral facial pain, pain in upper 
teeth, pain worsening at bending forward, 
and double sickening (two phases in the same 
illness period) prior to first visit, each scored 
one point. Nasal obstruction, rhinorrhoea, 
sinus pain, and malaise as estimated by the 
patient, gave a maximum of one point each. 
Rectal temperature between 37.6°C and 
Age of 15 years or younger, pregnancy, 
ongoing antibiotic treatment, immuno-
suppressive treatment, previous operations in 
the nose/sinus region, abuse of alcohol or 
narcotics, rheumatic disease, and penicillin 
allergy. If the symptoms had persisted more 
than 30 days, the patient was excluded due to 
a possible chronic sinusitis. Patients with 
high fever and considerable pain (due to 
ethical considerations) 
self-rating (restored, much better, 
somewhat better, unimproved, 
worse) without a more specific 
definition of these terms 
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38.0°C scored 0.5 points and above 38.0°C 1 
point. Purulent secretion in the nasal floor, 
which is a fairly consistent sign of purulent 
sinusitis, was given 2 points. The points were 
summated for each patient, resulting in a 
“clinical severity score” of maximum 13 
points. 
Merenstein, 
2005 [13] 
Suburban primary 
care office, between 
October 1, 2001 
and March 31, 
2003, USA 
Patients were eligible to participate if they 
were 18 years or older; had at least 1 cardinal 
feature described by the clinical prediction 
rule: 1) purulent nasal discharge 
predominating on one side, 2) local facial 
pain predominating on one side, 3) purulent 
nasal discharge on both sides, or 4) pus in the 
nasal cavity; and had symptoms for at least 7 
days. 
antibiotic treatment within the past month, 
allergy to penicillin, sinus surgery, 
compromised immunity, pneumonia, or 
streptococcal pharyngitis 
self-rating (entirely improved, not 
improved) without a more specific 
definition of these terms 
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Supplementary Table 2: Frequency of reported adverse events by group 
 
Author, year Garbutt, 2012 (38) Hadley, 2010 (39) Haye, 1998 (40) Lindbaek, 1996 (11) Lindbaek, 1998 (12) Merenstein, 2005 
(13) 
Type of AE 
Amoxici
llin  
n (%) 
Placebo  
n (%) 
Moxiflo
xacin 
n (%) 
Placebo 
n (%) 
Azithro
mycin  
n (%) 
Placeb
o 
n (%) 
Penicilli
n V  
n (%) 
Amoxic
illin  
n (%) 
Placebo 
n (%) 
Penicilli
n V  
n (%) 
Amoxici
llin  
n (%) 
Placebo 
n (%) 
Amoxic
illin  
n (%) 
Placebo 
n (%) 
Abdominal pain 4 (5)* n.r.   3 (3.4) 1 (1.2)       2 (3.5) 1 (1.7) 
Diarrhea 8 (9)* n.r. 5 (2) 2 (1.6) 11 (12.6) 5 (6.1) 15 (37) 21 (47) 5 (11)    4 (7) 1 (1.7) 
Dizziness   6 (2.4) 0 (0)         3 (5.3) 0 (0) 
Dry mouth             1 (1.8) 0 (0) 
Excessive tiredness 9 (11) 17 (21)             
Gastrointestinal 
side-effects 
         1 (5) 2 (9.1) n.r.   
Headache/asthenia 19 (22) 19 (23)     4 (10) 5 (11) 6 (14)      
Hot flashes             0 (0) 1 (1.7) 
Jittery             0 (0) 1 (1.7) 
Nausea/vomiting 6 (7)* n.r.   7 (8) 1 (1.2) 10 (24) 14 (31) 5 (11)    5 (8.8) 5 (8.5) 
Rash       0 (0) 5 (11) 2 (5)    2 (3.5) 0 (0) 
Vaginal discharge       0 (0) 5 (11) 1 (2)      
Vaginal infection 5 (6)* n.r.           2 (3.5) 0 (0) 
n.r. not reported, AE adverse event, * Reported numbers mentioning that there were no differences between study groups 
 
